BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26545722)

  • 1. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
    Bam R; Khan S; Ling W; Randal SS; Li X; Barlogie B; Edmondson R; Yaccoby S
    BMC Cancer; 2015 Nov; 15():864. PubMed ID: 26545722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
    Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
    Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells.
    Tsujimoto T; Lisukov IA; Huang N; Mahmoud MS; Kawano MM
    Blood; 1996 Apr; 87(8):3375-83. PubMed ID: 8605355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma and bone marrow mesenchymal stem cells' crosstalk: Effect on translation initiation.
    Attar-Schneider O; Zismanov V; Dabbah M; Tartakover-Matalon S; Drucker L; Lishner M
    Mol Carcinog; 2016 Sep; 55(9):1343-54. PubMed ID: 26293751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Granulocyte Colony-Stimulating Factor on Immune-Modulatory Cytokines in the Bone Marrow Microenvironment and Mesenchymal Stem Cells of Healthy Donors.
    Ok Bozkaya I; Azik F; Tavil B; Koksal Y; Ozguner M; Tunc B; Uckan Cetinkaya D
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1888-94. PubMed ID: 26265462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.
    Jakubikova J; Cholujova D; Hideshima T; Gronesova P; Soltysova A; Harada T; Joo J; Kong SY; Szalat RE; Richardson PG; Munshi NC; Dorfman DM; Anderson KC
    Oncotarget; 2016 Nov; 7(47):77326-77341. PubMed ID: 27764795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
    Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
    Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures.
    Lokhorst HM; Lamme T; de Smet M; Klein S; de Weger RA; van Oers R; Bloem AC
    Blood; 1994 Oct; 84(7):2269-77. PubMed ID: 7919345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.
    Xu S; Menu E; De Becker A; Van Camp B; Vanderkerken K; Van Riet I
    Stem Cells; 2012 Feb; 30(2):266-79. PubMed ID: 22102554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.
    Wallace SR; Oken MM; Lunetta KL; Panoskaltsis-Mortari A; Masellis AM
    Cancer; 2001 Apr; 91(7):1219-30. PubMed ID: 11283920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
    Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
    Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma.
    Kassen D; Moore S; Percy L; Herledan G; Bounds D; Rodriguez-Justo M; Croucher P; Yong K
    Br J Haematol; 2014 Oct; 167(2):194-206. PubMed ID: 25079197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential response of encapsulated nucleus pulposus and bone marrow stem cells in isolation and coculture in alginate and chitosan hydrogels.
    Naqvi SM; Buckley CT
    Tissue Eng Part A; 2015 Jan; 21(1-2):288-99. PubMed ID: 25060596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of in vitro growth of multiple myeloma cells.
    Zlei M; Egert S; Wider D; Ihorst G; Wäsch R; Engelhardt M
    Exp Hematol; 2007 Oct; 35(10):1550-61. PubMed ID: 17889722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.
    Kim J; Denu RA; Dollar BA; Escalante LE; Kuether JP; Callander NS; Asimakopoulos F; Hematti P
    Br J Haematol; 2012 Aug; 158(3):336-46. PubMed ID: 22583117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.
    Garcia-Gomez A; De Las Rivas J; Ocio EM; Díaz-Rodríguez E; Montero JC; Martín M; Blanco JF; Sanchez-Guijo FM; Pandiella A; San Miguel JF; Garayoa M
    Oncotarget; 2014 Sep; 5(18):8284-305. PubMed ID: 25268740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells' phenotype and translation initiation.
    Dabbah M; Attar-Schneider O; Tartakover Matalon S; Shefler I; Jarchwsky Dolberg O; Lishner M; Drucker L
    Carcinogenesis; 2017 Jul; 38(7):708-716. PubMed ID: 28838065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner.
    Ibraheem A; Attar-Schneider O; Dabbah M; Dolberg Jarchowsky O; Tartakover Matalon S; Lishner M; Drucker L
    Transl Res; 2019 May; 207():83-95. PubMed ID: 30738861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.